FAQ: NanoViricides Presentation at PODD 2025 Conference and Antiviral Drug Pipeline
Summary
NanoViricides, Inc. will present at the PODD 2025 Conference in Boston, providing updates on their antiviral drug pipeline and platform technologies. The company's lead candidate NV-387 is advancing toward Phase II trials for MPox and respiratory viral infections, with preclinical studies showing efficacy against multiple viruses.
What is the main announcement in this content?
NanoViricides, Inc. will present at the PODD 2025 Conference on October 27, 2025, where President and Executive Chairman Anil R. Diwan, PhD will provide updates on the company’s antiviral drug pipeline and platform technologies available for licensing.
Where and when will the PODD 2025 Conference presentation take place?
The presentation will occur on Monday, October 27, 2025, at 3 p.m. ET in Track 5A at the Westin Copley Hotel in Boston.
What is NanoViricides’ lead drug candidate and what conditions is it targeting?
The lead drug candidate is NV-387, a broad-spectrum antiviral drug advancing toward Phase II trials for MPox and respiratory viral infections, with plans to develop it as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections.
What preclinical results have been shown for NV-387?
Preclinical studies have shown strong efficacy against RSV, Influenza A, and Coronaviruses, demonstrating the drug’s broad-spectrum antiviral capabilities.
What is NanoViricides’ business model and technology foundation?
The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific antiviral applications, using nanoviricide technology that creates special purpose nanomaterials for antiviral therapy based on intellectual property from TheraCour.
What other viral diseases is NanoViricides developing drugs against?
The company is developing drugs against oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, Ebola virus, and has advanced candidate NV-HHV-1 for Shingles treatment.
Where can I find more detailed information about this announcement?
The full press release can be viewed at https://ibn.fm/Z4d0g and more company information is available at www.nanoviricides.com.
What is the current status of NanoViricides’ drug development timeline?
The company is currently focused on advancing NV-387 into Phase II human clinical trials but cannot project exact dates for filing INDs due to dependence on external collaborators and consultants.
What licensing agreements does NanoViricides have for its technology?
The company holds worldwide exclusive perpetual licenses from TheraCour for treating multiple viral diseases including HIV/AIDS, Hepatitis B/C, Rabies, Herpes, Influenza, Dengue, Ebola, and Coronaviruses, and intends to obtain licenses for RSV, Poxviruses, and/or Enteroviruses if initial research is successful.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 265899